Canada's NeuPath Health Q1 revenue rises 11% on increased patient visits

NeuPath Health

14/05/2026 12:42

Overview

Canada chronic pain clinic operator's Q1 revenue rose 11% yr/yr

Adjusted EBITDA for Q1 increased 15% yr/yr

Revenue growth driven by increased patient visits and improved capacity utilization

Outlook

Company expects new Guelph, Ontario location to open to patients in late Q3

Company remains focused on onboarding new physicians to support growth

NeuPath says it is looking to expand service offerings and footprint across Canada

Result Drivers

PATIENT VOLUME - Increased patient visits contributed to higher clinic revenue

CAPACITY UTILIZATION - Improved use of clinic space raised capacity utilization to 52% from 47% a year earlier

PHYSICIAN REIMBURSEMENT & SERVICE MIX - Positive adjustments to physician reimbursement rates and growth from Arthrosamid and fluoroscopy revenues supported revenue growth

Company press release: ID:nBw1VcR1ya

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
C$21.50 mln
C$23 mln (1 Analyst)
Q1 Adjusted EBITDA
C$1.5 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for NeuPath Health Inc is C$0.77, about 36.6% above its May 13 closing price of C$0.56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)